Skip to content
US & Canada

Pharma, biotech and radiopharma news

Drug discovery, major trial results, mergers, partnerships and new capacity across the US and Canada. Sources on every story.

ResearchNov 18, 2026

SELLAS Vaccine Cuts Death Risk 41% in Phase 3 Leukemia Trial

In a 126-patient phase 3 AML trial, median survival was 24.0 months on the SELLAS vaccine GPS versus 14.7 months on best available treatment.

SELLAS Life Sciencesacute myeloid leukemiacancer vaccine
MarketNov 17, 2026

Lilly's 15th Buyout of 2026 Is Up to $1.5B for Blood Cancer Startup

Lilly agreed to buy Calytrix Bio, a Massachusetts startup with an early antibody for two rare blood cancers, for up to $1.5 billion in cash.

Eli LillyCalytrix Bioacquisitions
RegulationNov 17, 2026

FDA Approves Roche Pill After 62% Cut in Progression or Death Risk

The FDA approved Roche's oral drug Wilserdly with everolimus for advanced breast cancer with an ESR1 mutation, four weeks ahead of its goal date.

RocheGenentechbreast cancer
IndustryNov 16, 2026

Cellectis to Cut Up to 70% of Staff After Dropping Its CAR-T Trials

Cellectis plans to cut up to 70% of staff over 2026 and 2027 as it stops its own CAR-T trials and shifts to in vivo gene editing for lipid disorders.

CellectislayoffsCAR-T
RegulationNov 16, 2026

FDA Turns Down Summit Lung Cancer Drug Tied to $2B AstraZeneca Deal

The FDA declined to approve Summit's ivonescimab in EGFR-mutated lung cancer because its phase 3 trial did not show a significant overall survival gain.

Summit TherapeuticsivonescimabFDA
IndustryNov 15, 2026

Lilly's $3.5B Pennsylvania Obesity Drug Site to Create 850 Jobs

Lilly broke ground on a $3.5 billion Lehigh Valley plant that will make injectables like retatrutide. It expects 850 jobs and an opening by 2031.

Eli LillymanufacturingPennsylvania
RadiopharmaNov 14, 2026

Moffitt Coalition Gets $47.3M to Build Florida Radiopharma Hub

A Moffitt-led group won $47.3 million in US funding for a Tampa Bay radiopharma hub, including $16.9 million toward an isotope and therapy plant.

Moffitt Cancer Centerradiopharmaceuticalsmedical isotopes
IndustryNov 14, 2026

Crinetics to Cut 78 Jobs Under Vertex After $10B Buyout

Crinetics, now owned by Vertex, will let go of 78 staff on Jan. 4, 2027, mostly in corporate roles. It disclosed the cuts about two months after the $10B deal closed.

Vertex PharmaceuticalsCrineticslayoffs
MarketNov 13, 2026

Blackstone to Fund Up to $1.5B of Pfizer's Obesity Shot Development

Blackstone will cover up to $1.5 billion of berobenatide development costs through 2028 in return for milestone payments, while Pfizer keeps full ownership of the drug.

PfizerBlackstoneobesity
RegulationNov 12, 2026

Novartis Reports 9 Tumours in Zolgensma Patients as FDA Investigates

Novartis says nine tumours have been reported in Zolgensma patients. The FDA says testing found the gene therapy's vector DNA in two of them and is weighing next steps.

NovartisZolgensmagene therapy
ResearchNov 12, 2026

Beam's Base-Edited Sickle Cell Therapy Meets 12-Month Trial Goal

Beam Therapeutics says risto-cel met its main goal of 12 months free of severe pain crises in sickle cell disease, and plans a US filing as early as year end.

Beam Therapeuticssickle cell diseasebase editing
RegulationNov 11, 2026

FDA Approves Merck KGaA Tumour Pill After 56% Respond in Trial

The FDA approved Merck KGaA's pimicotinib, sold as Pimjetmi, for TGCT. In a 94-patient trial, 56% on the drug responded at week 25, compared with 3% on placebo.

FDA approvalMerck KGaAEMD Serono
MarketNov 11, 2026

Argenx to Pay $550M Upfront in Up to $1.15B Peptide Biotech Buyout

Argenx will pay $550 million in cash upfront, and up to $595 million more in milestones, for Santa Cruz peptide biotech Unnatural Products.

argenxUnnatural Productsacquisitions
RadiopharmaNov 10, 2026

Lantheus to Sell New Jersey Radiopharma Plant and CDMO to PharmaLogic

PharmaLogic agreed to buy Lantheus's contract manufacturing business and its Springfield, New Jersey site, and will make Lantheus's lutetium Lu 177 dotatate.

radiopharmaceuticalsCDMOLantheus
RegulationNov 10, 2026

FDA Approves Bayer's Sunharbo After It Cut Stroke Risk 26%

The FDA approved Bayer's Sunharbo for adults after a recent non-cardioembolic ischemic stroke or high-risk TIA. It is the first Factor XIa inhibitor approved in the US.

BayerFDA approvalstroke
IndustryNov 9, 2026

Pfizer Plans $650M Groton Plant to Make Drugs for Its Own Trials

Pfizer will spend USD 650 million over five years on a 220,000 square foot Groton, Connecticut site to make drugs for its clinical trials.

PfizermanufacturingConnecticut
ResearchNov 9, 2026

Vir's Hepatitis Delta Combo Leaves Virus Undetectable in 79%

Vir's monthly elebsiran and tobevibart regimen met its phase 3 goal in hepatitis delta, with 44% reaching the combined endpoint at week 48.

Vir Biotechnologyhepatitis deltaphase 3
MarketNov 8, 2026

Boehringer Pledges $358M, Up to $7B More, for 6 Sino Cancer Programs

Boehringer Ingelheim takes options on six preclinical ADC and T-cell engager programs from SBP Group for US$358 million near term and up to US$7 billion in milestones.

Boehringer IngelheimSino Biopharmaceuticallicensing
IndustryNov 8, 2026

Agios Cuts Over 100 R&D Roles While FDA Delays Sickle Cell Ruling

Agios will cut more than 100 R&D roles, over 35% of its R&D staff, as the FDA pushes its sickle cell decision on mitapivat to Feb. 1, 2027.

Agioslayoffsmitapivat
MarketNov 7, 2026

Rhythm Shares Jump 28% on Reported AstraZeneca Takeover Bid

Rhythm shares closed up 28% after a report of an AstraZeneca offer. Reuters later put the non-binding bid at up to $134 a share. Neither firm has confirmed it.

AstraZenecaRhythm PharmaceuticalsM&A